Age Groups | Gout Status | N | ED Cases | Followup Time, PY | Mean Followup, Yrs | Incidence Rate, Cases per 1000 PY (95% CI) | Age-, Sex-, BMI-matched, HR (95% CI)* | + GP Visits, Socioeconomic Deprivation Index, BMI, Smoking, and Alcohol, Adjusted HR (95% CI) | + Comorbidity and CVD Drug Classes, Adjusted HR** (95% CI) |
---|---|---|---|---|---|---|---|---|---|
Total | Yes | 38,438 | 2290 | 192,401.1 | 5.0 | 11.90 (11.42–12.40) | 1.13 (1.08–1.19) | 1.10 (1.04–1.15) | 1.15 (1.09–1.21) |
No | 154,332 | 8447 | 804,958.6 | 5.2 | 10.49 (10.27–10.72) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | |
< 50 | Yes | 6595 | 451 | 36,336.2 | 5.5 | 12.41 (11.29–13.61) | 1.13 (1.01–1.26) | 1.10 (0.98–1.23) | 1.14 (1.02–1.29) |
No | 25,870 | 1594 | 143,607.9 | 5.6 | 11.10 (10.56–11.66) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | |
50–59 | Yes | 8686 | 817 | 47,911.3 | 5.5 | 17.05 (15.90–18.26) | 1.14 (1.05–1.24) | 1.11 (1.03–1.21) | 1.15 (1.06–1.25) |
No | 35,117 | 2973 | 201,636.7 | 5.7 | 14.74 (14.22–15.28) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | |
60–69 | Yes | 10,146 | 737 | 53,303.0 | 5.3 | 13.83 (12.85–14.86) | 1.15 (1.05–1.25) | 1.11 (1.02–1.21) | 1.18 (1.07–1.28) |
No | 41,309 | 2762 | 225,662.1 | 5.5 | 12.24 (11.79–12.70) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | |
≥ 70 | Yes | 13,011 | 285 | 54,850.5 | 4.2 | 5.20 (4.61–5.84) | 1.07 (0.93–1.23) | 1.03 (0.89–1.18) | 1.14 (0.98–1.32) |
No | 52,036 | 1118 | 234,051.9 | 4.5 | 4.78 (4.50–5.07) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
↵* Matched by age, sex, BMI, and entry time.
↵** Comorbidities include hypertension, diabetes, stroke, ischemic heart disease, hyperlipidemia; CVD drugs include angiotensin-converting enzyme inhibitors, aspirin, angiotensin II receptor blockers, β blockers, calcium channel blockers, and diuretics. ED: erectile dysfunction; PY: person-years; BMI: body mass index; GP: general practitioner; CVD: cardiovascular disease.